Bilsky E J, Inturrisi C E, Sadée W, Hruby V J, Porreca F
Department of Pharmacology, University of Arizona, Tucson 85724, USA.
Pain. 1996 Dec;68(2-3):229-37. doi: 10.1016/s0304-3959(96)03185-5.
N-Methyl-D-aspartate (NMDA) receptor antagonists have been shown to block the development of antinociceptive tolerance to morphine. Assessment of the effects of NMDA antagonists on development of antinociceptive tolerance to selective opioid mu (mu) and delta (delta) agonists, however, has not been reported. In these experiments, selective mu and delta receptor agonists, and morphine, were repeatedly administered to mice either supraspinally (i.c.v.) or systemically (s.c.), alone or after pretreatment with systemic NMDA antagonists. Antinociception was evaluated using a warm-water tail-flick test. Repeated i.c.v. injections of mu agonists including morphine, fentanyl, [D-Ala2, NMePhe4, Gly-ol]enkephalin (DAMGO) and Tyr-Pro-NMePhe-D-Pro-NH2 (PL017) or [D-Ala2, Glu4]deltorphin, a delta agonist, or s.c. injections of morphine or fentanyl, produced antinociceptive tolerance as shown by a significant rightward displacement of the agonist dose-response curves compared to controls. Single injections or repeated administration of MK801 (a non-competitive NMDA antagonist) or LY235959 (a competitive NMDA antagonist) at the doses employed in this study did not produce behavioral toxicity, antinociception or alter the acute antinociceptive effects of the tested opioid agonists. Consistent with previous reports, pretreatment with MK801 or LY235959 (30 min prior to agonist administration throughout the tolerance regimen) prevented the development of antinociceptive tolerance to i.c.v. or s.c. morphine. Neither NMDA antagonist, however, affected the development of antinociceptive tolerance to i.c.v. fentanyl, DAMGO, or [D-Ala2, Glu4]deltorphin. Additionally, MK801 pretreatment did not affect the development of antinociceptive tolerance to i.c.v. PL017 or to s.c. fentanyl. Further, MK801 pretreatment also did not affect the development of tolerance to the antinociception resulting from a cold-water swim-stress episode, previously shown to be a delta-opioid mediated effect. These data lead to the suggestion that the mechanisms of tolerance to receptor selective mu and delta opioids may be regulated differently from those associated with morphine. Additionally, these findings emphasize that conclusions reached with studies employing morphine cannot always be extended to 'opiates' in general.
N-甲基-D-天冬氨酸(NMDA)受体拮抗剂已被证明可阻断对吗啡的抗伤害感受耐受性的形成。然而,尚未有关于NMDA拮抗剂对选择性阿片μ(μ)和δ(δ)激动剂抗伤害感受耐受性形成影响的评估报告。在这些实验中,选择性μ和δ受体激动剂以及吗啡,单独或在经全身NMDA拮抗剂预处理后,通过脊髓上(脑室内注射)或全身(皮下注射)反复给予小鼠。使用温水甩尾试验评估抗伤害感受。反复脑室内注射μ激动剂,包括吗啡、芬太尼、[D-丙氨酸2,N-甲基苯丙氨酸4,甘氨酸-醇]脑啡肽(DAMGO)和酪氨酰-脯氨酰-N-甲基苯丙氨酸-D-脯氨酰胺(PL017)或δ激动剂[D-丙氨酸2,谷氨酸4]强啡肽,或皮下注射吗啡或芬太尼,均产生了抗伤害感受耐受性,表现为与对照组相比激动剂剂量-反应曲线显著右移。在本研究中使用的剂量下,单次注射或反复给予MK801(一种非竞争性NMDA拮抗剂)或LY235959(一种竞争性NMDA拮抗剂)均未产生行为毒性、抗伤害感受或改变所测试阿片类激动剂的急性抗伤害感受作用。与先前的报告一致,用MK801或LY235959预处理(在整个耐受性方案中在激动剂给药前30分钟)可防止对脑室内或皮下注射吗啡的抗伤害感受耐受性的形成。然而,两种NMDA拮抗剂均未影响对脑室内注射芬太尼、DAMGO或[D-丙氨酸2,谷氨酸4]强啡肽的抗伤害感受耐受性的形成。此外,MK801预处理不影响对脑室内注射PL017或皮下注射芬太尼的抗伤害感受耐受性的形成。此外,MK801预处理也不影响对冷水游泳应激发作所致抗伤害感受耐受性的形成,先前已证明这是一种δ阿片介导的效应。这些数据表明,对受体选择性μ和δ阿片类药物耐受性的机制可能与吗啡相关的机制调控方式不同。此外,这些发现强调,使用吗啡的研究得出的结论不能总是一概而论地推广到“阿片类药物”。